GHRP-2 (pralmorelin): what it is, how people use it, and what the evidence shows

GHRP-2 is one of the older and more potent names in the growth-hormone-peptide world, sold as a way to raise your own growth hormone for muscle, recovery, and appetite, and often confused with the newer, cleaner ipamorelin. The marketing tends to lead with how strongly it spikes growth hormone and to leave out everything that comes with that spike. This page puts it back. It explains what GHRP-2 actually is, how it is thought to work, what its short human studies do and do not show, what is known and unknown about its safety, and how it compares with its closest relatives, with a primary source for every claim. It is educational only, and nothing here is medical advice. For the wider map of approved drugs and unapproved research peptides that GHRP-2 belongs to, start with our cross-therapy explainer on what peptides are.

What is GHRP-2?

GHRP-2 is a synthetic hexapeptide, a chain of six amino acids, and it belongs to a family of compounds called growth hormone-releasing peptides that were invented in a lab rather than found in the body. The family traces to the American endocrinologist Cyril Bowers, who noticed in the late 1970s and early 1980s that certain analogs of enkephalin unexpectedly released growth hormone from pituitary cells. GHRP-6 was the first synthetic peptide shown to release growth hormone in a specific, dose-related way, and GHRP-2 and hexarelin were the hexapeptides synthesized afterward from that starting point. GHRP-2 is also known by the international drug name pralmorelin and by the old development code KP-102.

The key point for anyone comparing it to other compounds is what class it sits in. A growth hormone secretagogue does not contain growth hormone; it is a signal that prompts your own pituitary gland to release the hormone it already makes. So GHRP-2 is not injected growth hormone, it is not testosterone, and it is not an anabolic steroid. It sits in a separate category from all three, and the three are constantly conflated online. It is also not the same molecule as ipamorelin, even though the two are often discussed together: ipamorelin was engineered later to be selective, while GHRP-2 is an earlier, less selective member of the same family. GHRP-2 does have one genuine clinical footprint that most peptides in this space lack. Its most established real-world use is as a diagnostic agent: a single injection is used to test the pituitary’s capacity to release growth hormone, a role in which its use is limited to Japan, where it is commercially available. That is a test given once under supervision, not a treatment, and it is a very different thing from the repeated self-injection the physique market promotes.

How is GHRP-2 thought to work?

GHRP-2 is thought to work by binding the ghrelin receptor and prompting the pituitary to secrete growth hormone, and almost everything specific about that mechanism comes from laboratory, animal, and short human pharmacology studies. The receptor in question is the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor the natural “hunger hormone” ghrelin uses, which is why GHRP-2 is described as a ghrelin mimetic. When it activates that receptor on the hormone-producing cells of the pituitary, it triggers a pulse of growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1). The marketed logic runs from there: more growth-hormone pulses are claimed to support muscle, fat loss, and recovery.

The part the marketing usually leaves out is that this receptor system does far more than release growth hormone. Ghrelin and the compounds that mimic it act across a range of tissues, with documented roles in gut motility and gastric acid secretion, sleep and wake rhythm, reward-seeking behavior, taste, and glucose metabolism. A molecule chosen for one effect is acting on a receptor with several jobs. There is a second, more specific catch with GHRP-2. Compared with the selective ipamorelin, the older peptides in this family are not clean at the pituitary: in healthy young adults, GHRP-2 released more growth hormone than growth hormone-releasing hormone did, but it also raised prolactin, and its ACTH and cortisol-releasing activity was similar to that of the standard corticotropin-releasing hormone stimulus. In other words, the same signal that spikes growth hormone also nudges the stress-hormone and prolactin axes. The honest framing is that these are plausible, partly demonstrated pharmacologic actions in cells, animals, and short human studies, not a demonstrated body-composition result in a person. “Raises growth hormone for an hour” is a real finding; it is not the same as “produces the advertised physique,” and that gap is the thing this kind of marketing most often blurs.

What is GHRP-2 studied and marketed for?

GHRP-2 is studied and marketed for three overlapping goals: physique and recovery, appetite, and growth-hormone testing. In the consumer market it is promoted, often stacked with a GHRH analog such as CJC-1295, for building lean muscle, losing fat, sharpening recovery and sleep, and a general “anti-aging” or “GH optimization” pitch. Read those as areas of marketing and hope, not proven uses: the wording of an advertisement (“supports lean-muscle growth”) and the wording of the science (“raised a hormone level for an hour in a small study”) are not the same claim. Because GHRP-2 is a ghrelin mimetic, appetite is the second theme, and here the effect is real and measured: it is one of the few peptides in this space with a controlled human study of the outcome, discussed in the next section.

The third use is the one with actual regulatory standing, and it is diagnostic rather than performance-related. Because a single injection reliably provokes growth-hormone release in people with a healthy pituitary but much less in those without one, GHRP-2 is used as a provocative test for growth hormone deficiency. Its ability to also stimulate the corticotrophs means the same test can concurrently probe the hypothalamic-pituitary-adrenal axis. That diagnostic role, not the physique pitch, is the one setting where GHRP-2 is a recognized clinical tool.

Because this overview is the definitional entry point, the network’s physique-focused publication examines the muscle-and-recovery claims in detail rather than asserting them here. For the honest version of that conversation, see what GH peptides are actually marketed for in physique circles, realistic expectations and side effects for GH peptides, how the class compares with anabolic steroids, and how injectable secretagogues stack up against the oral option in MK-677 versus GH peptides. Treat each of those as “being marketed,” not “established.” The marketing describes the outcome people want; the evidence section below describes what has actually been shown.

What does the evidence actually show?

The evidence for GHRP-2 is real but narrow: it reliably raises growth hormone in the short term, and it increases appetite, but no completed trial shows it delivers the physique, recovery, or anti-aging outcomes it is sold for. The short-term hormone effect is well documented. In healthy young adults, an intravenous dose released more growth hormone than growth hormone-releasing hormone did, and that potency is exactly why it works as a diagnostic. As a provocative test in adults, a 100-microgram intravenous dose diagnosed severe growth hormone deficiency with high reliability using a peak-GH cut-off, with favorable reproducibility and tolerability. Those are solid findings, but note what they measure: a hormone level over minutes to an hour, in a controlled clinical setting, not muscle gained or fat lost.

The appetite finding is the other genuinely human piece, and it cuts against the “lean physique” pitch as much as it supports the “ghrelin mimetic” label. In a controlled study of seven lean, healthy men, a subcutaneous infusion of GHRP-2 made subjects eat about 36 percent more food than they did on saline, the first demonstration that GHRP-2, like ghrelin, increases food intake in humans. That is a real, measured effect, and it is a reminder that the compound does more than raise growth hormone.

What is missing is the part the marketing assumes. There is no completed, published, randomized trial showing that GHRP-2 builds muscle, reduces fat, speeds recovery, or slows aging in healthy adults. The case for those uses rests on growth-hormone-release pharmacology and short-term hormone measurements, extended by analogy to what growth hormone is presumed to do. This does not prove GHRP-2 does nothing. It means the studies that could show whether it delivers the advertised results in people have not been run, while the one thing it clearly does over time, stimulate appetite, is rarely the thing buyers are told to expect. Preclinical and short-term promise and human proof are different things, and for its physique claims GHRP-2 sits almost entirely on the promise side of that line.

What are the reported side effects and safety unknowns?

GHRP-2’s long-term safety in healthy people is largely unknown, because it has barely been studied for the way the physique market actually uses it: months of self-administered injections rather than a single supervised diagnostic dose. Its short diagnostic use is well tolerated, but that record describes one injection in a monitored clinic, not sustained use. The clearer near-term concern is that GHRP-2 is not selective. The same studies that made it useful as a growth-hormone stimulus also showed it raises prolactin and drives ACTH and cortisol, and later work in patients found evidence for direct ACTH-releasing activity, meaning the stress-hormone effect is a property of the molecule rather than an incidental artifact. Chronically nudging prolactin and cortisol is not a neutral thing to do, and it is precisely the trade-off that motivated the development of selective alternatives.

There are also mechanism-based reasons for caution beyond the stress hormones. GHRP-2 acts on a receptor system that also governs appetite, gut motility, and glucose metabolism, so increased hunger and metabolic effects are biologically expected rather than surprising, and pushing the growth-hormone and IGF-1 axis upward over months is not consequence-free. Layered on top of the biology is a product-quality problem specific to how these peptides are sold. A “research use only” vial is not required to be sterile, to contain the labeled dose, or to be free of contaminants. Forensic testing shows this is not hypothetical: a 2018 peer-reviewed analysis of falsified peptide drugs, most obtained from illegal internet sources, found purity ranging from 5 percent to 75 percent and toxic elemental impurities including arsenic well above the limit for injectable drugs. So the safety picture stacks two uncertainties at once: what a non-selective secretagogue does in a healthy body over time, and whether an unregulated vial even contains what its label claims at an injectable purity. Our companion explainer on what the evidence shows about peptide side effects walks through both the documented risks and the unknowns.

How does GHRP-2 compare with GHRP-6 and ipamorelin?

All three act on the same ghrelin receptor, but they differ in how cleanly they do it. GHRP-2 is the stronger, older and less selective option; GHRP-6 is its close sibling, best known for hunger; and ipamorelin was engineered later specifically to raise growth hormone without the stress-hormone and prolactin effects. The table summarizes what the cited studies show, which is mostly short-term hormone data rather than physique outcomes. PeptideAgent’s GHRP-2 vs GHRP-6 comparison adds the regulatory difference: GHRP-2 is approved in Japan, as pralmorelin, as a diagnostic test for growth hormone deficiency, while GHRP-6 has never been approved for any use.

The practical reading is that “more growth hormone” from GHRP-2 comes bundled with more cortisol, more prolactin and more appetite, which is the trade-off that led researchers to build selective alternatives. For the full picture on each, see our GHRP-6 and ipamorelin overviews.

Is GHRP-2 banned in sport?

Yes. The World Anti-Doping Agency lists it by name, as pralmorelin, among the growth hormone secretagogues prohibited at all times under class S2, so any athlete in a tested sport should treat it as prohibited.

How to think about GHRP-2

If you are weighing GHRP-2, the most useful move is to separate the chemistry from the claims. The chemistry is real and genuinely potent, an older growth hormone secretagogue that raises growth hormone strongly, along with prolactin and cortisol, and that has a real diagnostic use. The claims about muscle, fat loss, recovery, and anti-aging are mostly hope, because no completed human trial has confirmed them, while the effect the human data do show, a substantial rise in appetite, is rarely the one buyers are promised.

If your actual goal is more muscle, less fat, better recovery, or a sense that your hormones are off, start with that goal, ideally with a licensed clinician who can order the right testing and weigh training and nutrition, treatment of an underlying issue such as poor sleep, or an approved medication where one is appropriate. It also helps to see how the GHRH analog CJC-1295 is meant to be paired with secretagogues like this one. Before evaluating any source, our sister publication is blunt about what to ask before you buy any peptide, and our physique spoke lays out what GH peptides do and do not do for physique.

Status: Not FDA-approved. What this status means.

Educational information only, not medical advice. Every scientific statement on this page is sourced to the primary references linked above. Updated October 12, 2026.